Founded in 1993 by Jerome Lemelson and his wife, Dorothy, the Foundation has devoted the past two decades to fostering creativity and celebrating the inventive spirit and has committed more than $150 million to improve lives through invention in the U.S and developing countries.

PaxVax is specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines.

Health Expense offers services to empower organizations and their employees to make informed healthcare choices that ultimately result in lower healthcare expenses and better quality of care.

Responsible for Medical and Scientific Affairs activities for the Legacy Novartis Diagnostics blood screening portfolio.

Manage team of industry experts to focus on transfusion medicine, transfusion-transmitted infection prevention and blood safety.

Implemented Clinical Operational Excellence program; Clinical trial activity included blood screening trials in China (Ultrio Plus assay on Procleix Tigris System and Ultrio Elite assay on the Procleix Panther System) and multi-center studies in Europe (Procleix Panther System) in support of launch.

Leader of Integration (Transformation) team activities related Research and Development during Novartis Vaccines & Diagnostics acquisition of Tianyuan Biopharm Vaccine Company in Linping Hangzhou, China.

Vaccines Development Liaison to the Business Development and Licensing group for Novartis Vaccines & Diagnostics. Managed activities for the development department (comprised of senior industry vaccine development experts) to support due diligence, alliance management, M&A and out-licensing activities, and regular presentations to the Deal Review Committee and Executive Committee.

Responsible for early clinical development plans and first-in-man proof of concept phase I clinical trials for novel vaccine candidates.

Key roles and accomplishments: Global Clinical Team Leader, Meningococcal C Conjugate Vaccine Program (Menjugate), registered in the UK in March 2000, in time for the National Immunization catch-up campaign of the population from 2-18 years of age. Subsequent clinical activities in infants supported follow on registration in infants and toddlers to support the routine national vaccination program.Meningococcal Clinical Franchise Leader: Responsible for Clinical Development Plans, (high performing) teams and Phase I-III Clinical trials in support of novel meningococcal vaccines in the Novartis Vaccines & Diagnostics portfolio (MenACWY, MenB).

Served within the Hospital Infections Program and National Nosocomial Infection Surveillance System. Managed outbreak investigations related to device associated infections, HBV infections associated with Dialysis Centers, and MRSA surgical site infections, and emerging drug resistant bacterial infections.